In vitro Inhibition of Brain Glutamic Acid Decarboxylase by Sodium 2-mercaptoethanesulphonate and Endogenous Thiols and its Possible in vivo Consequences
Restricted accessResearch articleFirst published online May, 1989
In vitro Inhibition of Brain Glutamic Acid Decarboxylase by Sodium 2-mercaptoethanesulphonate and Endogenous Thiols and its Possible in vivo Consequences
Meanwell C., Blake AE, Blackledge G., et al. Encephalopathy associated with ifosfamide/mesna therapyLancet1985; i: 406-7.
2.
Cantwell Bmj & Harris ALIfosfamide/mesna and encephalopathyLancet1985; i: 752.
3.
Lamar C.Mercaptopropionic acid: a convulsant that inhibits glutamate decarboxylaseJournal of Neuro-chemistry1970; 17: 165-70.
4.
VanDyk JJ, Falkson HC, van der Merwe AM & Falkson G.Unexpected toxicity in patients treated with ifosfamideCancer Research1972; 32: 921-4.
5.
Albers RW & Brady ROThe distribution of glutamic decarboxylase in the nervous system of the Rhesus monkey. Journal of Biological Chemistry1959 ; 234: 926-8.
6.
Oldendorf WHBrain uptake of radiolabelled amino acids, amines and hexoses after arterial injection. American Journal of Physiology1971; 222: 1629-39.
7.
Shaw IC & Graham MIMesna-a short review. Cancer Treatment Reviews1987; 14: 67-86.
8.
Sidau B. & Shaw ICDetermination of sodium 2-mercaptoethanesulphonate by HPLC using post column reaction colorimetry or electrochemical detection. Cancer Treatment Reviews1984; 311: 234-8.
9.
Wright KE, Garrod P. & Shaw ICMechanism of enhanced cysteine excretion in urine during sodium 2-mercaptoethanesulphonate (mesna) administrationHuman Toxicology1985 ; 4: 456.
10.
Sangster G. , Kaye SV, Calman KC & Dalton JFFailure of 2-mercaptoethanesulphonate sodium (mesna) to protect against ifosfamide nephrotoxicityEuropean Journal of Cancer and Clinical Pharmacology1984; 20: 435-6.
